Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Pillinger

Showing results (11-20 of 148) with videos related to

Pageof 15
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|January 19, 2019
Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et alAryeh M Abeles, Michael H Pillinger
Current Rheumatology Reports|December 9, 2010
The next generation of gout therapeutics: ready for prime time?Aryeh M Abeles, Michael H Pillinger
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2010
New treatments for goutJanet B Mapa, Michael H Pillinger
Current Rheumatology Reports|April 29, 2010
Such sweet sorrow: fructose and the incidence of goutMichael H Pillinger, Aryeh M Abeles
Arthritis & Rheumatology (Hoboken, N.J.)|October 18, 2016
Editorial: The Sound and the Fury: Musculoskeletal Ultrasound in the Diagnosis of GoutEugene Y Kissin, Michael H Pillinger
Seminars in Arthritis and Rheumatism|July 5, 2020
Therapeutic approaches in the treatment of goutMichael H Pillinger, Brian F Mandell
Current Opinion in Rheumatology|January 3, 2019
Gout and cardiovascular disease: crystallized confusionAryeh M Abeles, Michael H Pillinger
Bulletin of the NYU Hospital for Joint Diseases|October 10, 2007
Interleukin-6 in the pathogenesis of rheumatoid arthritisJean Y Park, Michael H Pillinger
Arthritis and Rheumatism|February 1, 2006
Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?Aryeh M Abeles, Michael H Pillinger
Clinical Immunology (Orlando, Fla.)|January 11, 2005
15d-PGJ2: the anti-inflammatory prostaglandin?Jose U Scher, Michael H Pillinger
Pageof 15

Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
Arthritis & Rheumatology (Hoboken, N.J.)|January 19, 2019
Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et alAryeh M Abeles, Michael H Pillinger
Current Rheumatology Reports|December 9, 2010
The next generation of gout therapeutics: ready for prime time?Aryeh M Abeles, Michael H Pillinger
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2010
New treatments for goutJanet B Mapa, Michael H Pillinger
Current Rheumatology Reports|April 29, 2010
Such sweet sorrow: fructose and the incidence of goutMichael H Pillinger, Aryeh M Abeles
Arthritis & Rheumatology (Hoboken, N.J.)|October 18, 2016
Editorial: The Sound and the Fury: Musculoskeletal Ultrasound in the Diagnosis of GoutEugene Y Kissin, Michael H Pillinger
Seminars in Arthritis and Rheumatism|July 5, 2020
Therapeutic approaches in the treatment of goutMichael H Pillinger, Brian F Mandell
Current Opinion in Rheumatology|January 3, 2019
Gout and cardiovascular disease: crystallized confusionAryeh M Abeles, Michael H Pillinger
Bulletin of the NYU Hospital for Joint Diseases|October 10, 2007
Interleukin-6 in the pathogenesis of rheumatoid arthritisJean Y Park, Michael H Pillinger
Arthritis and Rheumatism|February 1, 2006
Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?Aryeh M Abeles, Michael H Pillinger
Clinical Immunology (Orlando, Fla.)|January 11, 2005
15d-PGJ2: the anti-inflammatory prostaglandin?Jose U Scher, Michael H Pillinger
Pageof 15